Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ezetimibe

Nature Reviews Drug Discovery volume 2, pages 97–98 (2003)Cite this article

Abstract

Ezetimibe (Zetia), the first in a new class of agents that inhibit cholesterol absorption in the intestine, was approved by the FDA in October 2002 for the reduction of cholesterol levels in patients with hypercholesterolaemia. What impact is it likely to have on the multi-billion-dollar market for cholesterol-lowering drugs?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structure of ezetimibe.
Figure 2: Global sales of anti-hyperlipidaemic drugs in US $ billion.
Figure 3: Patent expirations of statins.

References

  1. Executive summary of the third report of the national cholesterol education program (NCEP) expert on detection, evaluation and treatment of high blood cholesterol (adult treatment panel III). JAMA 285, 2486–2497 (2001).

  2. Burnett, D. A., Caplen, M. A., Davis, H. R. Jr, Burrier, R. E. & Clader, J. W. 2-azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. 37, 1733–1736 (1994).

    Article  CAS  Google Scholar 

  3. Clader, J. W. et al. 2-azetidinone cholesterol absorption inhibitors: structure–activity relationships on the heterocyclic nucleus. J. Med. Chem. 39, 3684–3693 (1996).

    Article  CAS  Google Scholar 

  4. Van Heek, M. A. et al. In vivo metabolism-based discovery of a potent cholesterol inhibitor, SCH 58235, in the rat and rhesus monkey through identification of the active metabolites of SCH 48461. J. Pharmacol. Exp. Therapeut. 283, 157–163 (1997).

    CAS  Google Scholar 

  5. Rosenblum, S. B. et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-4S-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41, 973–980 (1998).

    Article  CAS  Google Scholar 

  6. FDA Drug Approvals List [online] (cited 6 Jan 2003) http://www.fda.gov/cder/foi/label/2002/21445lbl.pdf

  7. Wu, G., Wong, Y., Chen, X. & Ding, Z. A novel one-step diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors. J. Org. Chem. 64, 3714–3718 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Decision Resources Intl, 50–51 Russell Square, London, WC1B 4HQ, UK

    John Earl & Peter Kirkpatrick

Authors
  1. John Earl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Earl.

Additional information

Peter Kirkpatrick is a Senior Editor of Nature Reviews Drug Discovery. John Earl is a Director

Rights and permissions

Reprints and permissions

About this article

Cite this article

Earl, J., Kirkpatrick, P. Ezetimibe. Nat Rev Drug Discov 2, 97–98 (2003). https://doi.org/10.1038/nrd1015

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1015

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing